Background: As the World Health Organization seeks to eliminate trachoma by 2020, countries are beginning to control the transmission of trachomatous inflammation-follicular (TF) and discontinue mass drug administration (MDA) with oral azithromycin. We evaluated the effect of MDA discontinuation on TF1-9 prevalence at the district level.
Methods: We extracted from the available data districts with an impact survey at the end of their program cycle that initiated discontinuation of MDA (TF1-9 prevalence <5%), followed by a surveillance survey conducted to determine whether TF1-9 prevalence remained below the 5% threshold, warranting discontinuation of MDA. Two independent analyses were performed, 1 regression based and 1 simulation based, that assessed the change in TF1-9 from the impact survey to the surveillance survey.
Results: Of the 220 districts included, TF1-9 prevalence increased to >5% from impact to surveillance survey in 9% of districts. Regression analysis indicated that impact survey TF1-9 prevalence was a significant predictor of surveillance survey TF1-9 prevalence. The proportion of simulations with >5% TF1-9 prevalence in the surveillance survey was 2%, assuming the survey was conducted 4 years after MDA.
Conclusion: An increase in TF1-9 prevalence may represent disease resurgence but could also be due to measurement error. Improved diagnostic tests are crucial to elimination of TF1-9 as a public health problem.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289551 | PMC |
| http://dx.doi.org/10.1093/infdis/jiz691 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trachoma risk factors in Oromia Region, Ethiopia.
PLoS Negl Trop Dis
November 2023
International Centre for Eye Health, Clinical Research Department, Faculty of Infectious and Tropical diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Background: Trachoma, the leading infectious cause of blindness, is caused by the bacterium Chlamydia trachomatis (Ct). Despite enormous disease control efforts and encouraging progress, trachoma remains a significant public health problem in 44 countries. Ethiopia has the greatest burden of trachoma worldwide, however, robust data exploring transmission risk factors and the association between socio-economic status is lacking from some regions.
View Article and Find Full Text PDFExploring water, sanitation, and hygiene coverage targets for reaching and sustaining trachoma elimination: G-computation analysis.
PLoS Negl Trop Dis
February 2023
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Article Synopsis
- Trachoma is a serious eye disease that can cause blindness, and improving water, sanitation, and hygiene (WaSH) is important to help prevent it.
- The study looked at how increasing access to clean water for washing faces and using toilets can reduce the number of children with trachoma.
- Findings suggest that having at least 65% of people using clean water for washing and 85% using proper toilets can help lower trachoma cases significantly.
Forecasting the elimination of active trachoma: An empirical model.
PLoS Negl Trop Dis
July 2022
RTI International, Washington DC, United States of America.
Background: Great progress has been made toward the elimination of trachoma as a public-health problem. Mathematical and statistical models have been used to forecast when the program will attain the goal of the elimination of active trachoma, defined as prevalence of trachomatous inflammation-follicular in 1-9 year olds (TF1-9) <5%. Here we use program data to create an empirical model predicting the year of attaining global elimination of TF1-9.
View Article and Find Full Text PDFTrachoma Prevalence After Discontinuation of Mass Azithromycin Distribution.
J Infect Dis
June 2020
Francis I Proctor Foundation, University of California, San Francisco, California, USA.
Background: As the World Health Organization seeks to eliminate trachoma by 2020, countries are beginning to control the transmission of trachomatous inflammation-follicular (TF) and discontinue mass drug administration (MDA) with oral azithromycin. We evaluated the effect of MDA discontinuation on TF1-9 prevalence at the district level.
Methods: We extracted from the available data districts with an impact survey at the end of their program cycle that initiated discontinuation of MDA (TF1-9 prevalence <5%), followed by a surveillance survey conducted to determine whether TF1-9 prevalence remained below the 5% threshold, warranting discontinuation of MDA.
One round of azithromycin MDA adequate to interrupt transmission in districts with prevalence of trachomatous inflammation-follicular of 5.0-9.9%: Evidence from Malawi.
PLoS Negl Trop Dis
June 2018
Clinical Research Department, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Background: As highly trachoma-endemic countries approach elimination, some districts will have prevalences of trachomatous inflammation-follicular in 1-9-year-olds (TF1-9) of 5.0-9.9%.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!